Cargando…

Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study

BACKGROUND: The aim of this study was to evaluate the survival benefit of radical surgery with additional extensive upper abdominal procedures (EUAS) for the treatment of stage IIIC and IV ovarian cancer with bulky upper abdominal disease (UAD). METHODS: An observational study was conducted between...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Yulan, Jiang, Rong, Yin, Sheng, You, Chao, Liu, Dongli, Cheng, Xi, Tang, Jie, Zang, Rongyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535562/ https://www.ncbi.nlm.nih.gov/pubmed/26268818 http://dx.doi.org/10.1186/s12885-015-1525-1

Ejemplares similares

Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer
por: Lim, Myong Cheol, et al.
Publicado: (2017)

Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?
por: Zang, Rongyu, et al.
Publicado: (2019)

Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept
por: Jiang, Rong, et al.
Publicado: (2020)

Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy
por: Blankenstein, Stephanie A., et al.
Publicado: (2020)

Tozzi classification of diaphragmatic surgery in patients with stage IIIC–IV ovarian cancer based on surgical findings and complexity
por: Tozzi, Roberto, et al.
Publicado: (2019)

Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer
por: Rutten, Marianne J., et al.
Publicado: (2015)

Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage IIIC and IV epithelial ovarian cancer
por: Forde, Gareth K, et al.
Publicado: (2016)

Long-Term Outcomes of Radical Surgery for Transverse Colon Cancer Staged from I to IIIC
por: Jiang, Yaofei, et al.
Publicado: (2020)

Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer
por: Luo, Yanlin, et al.
Publicado: (2016)

Bowel resection rate but not bowel related morbidity is decreased after interval debulking surgery compared to primary surgery in patents with stage IIIC–IV ovarian cancer
por: Tozzi, Roberto, et al.
Publicado: (2018)

Cytoreductive surgery in ovarian cancer
por: Pomel, Christophe, et al.
Publicado: (2007)

Erratum: Bowel resection rate but not bowel related morbidity is decreased after interval debulking surgery compared to primary surgery in patents with stage IIIC–IV ovarian cancer
por: Tozzi, Roberto, et al.
Publicado: (2019)

The prognosis of women with stage IB1-IIB node-positive cervical carcinoma after radical surgery
por: Cheng, Xi, et al.
Publicado: (2004)

Hypoxic isolated abdominal perfusion breaks through chemoresistance in recurrent FIGO stage IIIC and IV ovarian cancer
por: Aigner, Karl R., et al.
Publicado: (2021)

Feasibility of laparoscopic diaphragmatic peritonectomy during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer
por: Tozzi, Roberto, et al.
Publicado: (2020)

Benefits of surgery in the multimodality treatment of stage IIB-IIIC small cell lung cancer
por: Yang, Yong, et al.
Publicado: (2019)

Prognostic analysis of patients with stage IIIC1p cervical cancer treated by surgery
por: Fan, Xiang, et al.
Publicado: (2023)

Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer
por: Angeles, Martina Aida, et al.
Publicado: (2021)

Splenectomy during cytoreductive surgery in epithelial ovarian cancer
por: Sun, Hengzi, et al.
Publicado: (2018)

Liver Resection as Part of Cytoreductive Surgery for Ovarian Cancer
por: Luna-Abanto, Jorge, et al.
Publicado: (2020)

Significance of cholecystectomy in cytoreductive surgery for advanced ovarian cancer
por: Son, Joo-Hyuk, et al.
Publicado: (2023)

The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer
por: Škof, Erik, et al.
Publicado: (2016)

Neo-adjuvant chemotherapy in stage IIIC potentially resectable epithelial ovarian cancer
por: Voutsadakis, Ioannis A.
Publicado: (2016)

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer
por: Xu, Xia, et al.
Publicado: (2016)

Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer
por: Lei, Ziying, et al.
Publicado: (2020)

Cytoreductive Surgery with the PlasmaJet Improved Quality-of-Life for Advanced Stage Ovarian Cancer Patients
por: Nieuwenhuyzen-de Boer, Gatske M., et al.
Publicado: (2023)

The current role of secondary cytoreductive surgery for recurrent ovarian cancer
por: de Bree, Eelco, et al.
Publicado: (2022)

Role of Laparotomy-based Parameters in Assessment of Optimal Primary Debulking Surgery and Long-term Outcomes in Patients with Stage IIIC Epithelial Ovarian Cancer
por: Zhou, Mingyi, et al.
Publicado: (2020)

Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer
por: Hoff, John, et al.
Publicado: (2014)

Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
por: Munoz-Zuluaga, Carlos A., et al.
Publicado: (2020)

Network of Mediators for Vascular Inflammation and Leakage Is Dysbalanced during Cytoreductive Surgery for Late-Stage Ovarian Cancer
por: Klaschik, Sven, et al.
Publicado: (2019)

Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer
por: Bogani, Giorgio, et al.
Publicado: (2018)

Rectosigmoid resection during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer: morbidity of gynecologic oncology vs. colorectal team
por: Tozzi, Roberto, et al.
Publicado: (2021)

Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
por: Shi, Tingyan, et al.
Publicado: (2022)

Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in Ovarian Cancer: An Umbrella Review of Meta-Analyses
por: Souadka, Amine, et al.
Publicado: (2022)

Simplified Selection Criteria for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer
por: Son, Joo-Hyuk, et al.
Publicado: (2022)

The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma
por: Nunes, Rafael Leite, et al.
Publicado: (2023)

Salvage cytoreductive surgery for patients with recurrent endometrial cancer: a retrospective study
por: Ren, Yulan, et al.
Publicado: (2014)

Preoperative Lymphocyte-Monocyte Ratio Is a Predictor of Suboptimal Cytoreduction in Stage III-IV Epithelial Ovarian Cancer
por: Eo, Wankyu, et al.
Publicado: (2016)

Survival Outcomes of Patients with International Federation of Gynecology and Obstetrics Stage IV Ovarian Cancer: Cytoreduction Still Matters
por: Xiao, Yao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4uqtir2huq5cirskoqgdcs0i13